November 1-2, 2019 - MD Anderson Cancer Center

UPDATE ON THE MANAGEMENT OF

14th Genitourinary Malignancies

November 1-2, 2019

The University of Texas MD Anderson Cancer Center Dan L. Duncan Building (CPB) Floor 8, Rooms 1-8 1155 Pressler Street Houston, Texas

Program Directors

Jose A. Karam, MD (Chair) Associate Professor Urology Matthew T. Campbell, MD (Co-Chair) Assistant Professor Genitourinary Medical Oncology Brian F. Chapin, MD (Co-Chair) Associate Professor Urology

UPDATE ON THE MANAGEMENT OF

14th Genitourinary Malignancies

Focus

This conference will highlight innovative, multidisciplinary and novel treatment approaches for the treatment of complex genitourinary malignancies for the practicing urologist and medical oncologist that might not be currently either available or feasible in their home practice. This activity will also inform practicing urologists and medical oncologists on ongoing research (clinical and translational) that will lead to further developments in our field that will lead to potentially fundamental changes in the treatment paradigm for patients with genitourinary malignancies. The long-term goals of this activity are that attendees are better equipped to treat patients with genitourinary malignancies, that there is an increased awareness of new developments and research in the and an increased utilization of multidisciplinary approaches to the treatment of patients.

Educational Objectives

After attending the conference, participants should be able to: ?Evaluate, counsel and treat patients with rare genitourinary malignancies (penile

cancer, testicular cancer, and germ cell tumors) (Knowledge, Competence, Performance, Patient Outcomes); ?Utilize surgery and therapies for patients with kidney cancer (small renal masses, locally advanced tumors/adjuvant therapy, metastatic tumors/cytoreductive surgery, and systemic therapy) (Knowledge, Competence, Performance, Patient Outcomes); ?Assess patients with urothelial carcinoma (molecular characterization, non-muscle invasive tumors, muscle-invasive tumors, and systemic therapy) (Knowledge, Competence); ?Evaluate, counsel and treat patients with prostate cancer (screening, early disease/ focal therapy, radiation therapy, high-risk disease, and recurrent/metastatic disease) (Knowledge, Competence, Performance, Patient Outcomes).

Educational Methods

Lecture/Didactic ? Case Study ? Panel Discussion ? Question and Answer Sessions ? Poster Session ? Skills- Based Training

Target Audience

This conference should be of value to Urologists, Medical Oncologists, Physician Assistants, and Advanced Nurse Practitioners.

Evaluation

A course evaluation will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation/Credit Designation

PHYSICIANS The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 15.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ETHICS

The session entitled, Heritable Genitourinary Cancers-When to Screen and What to Do Next, has been designated by The University of Texas MD Anderson Cancer Center for 1.00 AMA PRA Category 1 CreditsTM in medical ethics and/or professional responsibility.

CME CERTIFICATES AND ATTENDANCE VERIFICATION CERTIFICATES Certificates awarding AMA PRA Category 1 CreditsTM or certificates documenting attendance will be emailed when an individual completes the online CME Verification process after the conference.

CALL FOR Abstracts

Abstracts will be selected for poster presentation at the conference. Please submit abstracts via e-mail to GUConference@.

MD Anderson Organizing Committee

PROGRAM DIRECTORS

Jose A. Karam, MD (Chair) Associate Professor Urology

Matthew T. Campbell, MD (Co-Chair) Assistant Professor Genitourinary Medical Oncology

Brian F. Chapin, MD (Co-Chair) Associate Professor Urology

CONFERENCE COMMITTEE

Ana Aparicio, MD Associate Professor Genitourinary Medical Oncology

Arlene Siefker-Radtke, MD Professor Genitourinary Medical Oncology

John Davis, MD Associate Professor Urology

Nizar M. Tannir, MD Professor and Ad-Interim Chairman Genitourinary Medical Oncology

Neema Navai, MD Associate Professor Urology

Christopher G. Wood, MD Professor and Vice Chairman Urology

Curtis A. Pettaway, MD Professor Urology

Carol Fourtunia Administrative Coordinator Urology

Amishi Shah, MD Assistant Professor Genitourinary Medical Oncology

Allison Baring, CMP CME Conference Planner CME Conference Management

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

AGENDA

Friday November 1, 2019

7:00 am Registration/Continental Breakfast

7:50

Welcome/Opening Remarks

Jose A. Karam, MD; Matthew T. Campbell, MD and Brian F. Chapin, MD

SESSION I: Renal Cell Carcinoma

Moderators:Christopher G. Wood, MD and Nizar M. Tannir, MD

Management of the Small Renal Mass: What is the Best Approach?

8:00

Active Surveillance

Surena Matin, MD

8:10

Ablation

Kamran Ahrar, MD

8:20

Partial Nephrectomy

Jeffrey J. Tomaszewski, MD

8:30

Question and Answer Session

Locally Advanced Renal Cell Carcinoma

8:45

Is There a Role for Neoadjuvant Therapy in the Management of Locally

Advanced Renal Cell Carcinoma?

Christopher G. Wood, MD

9:00

Update on Adjuvant Therapy in Kidney Cancer: Recent Results and

Ongoing Trials

Jose A. Karam, MD

9:15

Question and Answer Session

9:30

Break

Metastatic Renal Cell Carcinoma: What is the Best First-Line Systemic Therapy for Intermediate/Poor Risk Clear-Cell RCC?

9:45

A PD-1 or PD-L1 Antibody + VEGF Targeted Therapy

Matthew T. Campbell, MD

9:55

Nivolumab + Ipilimumab

Jianjun Gao, MD, PhD

What is the Best First-Line Systemic Therapy for Favorable-Risk Clear-Cell RCC?

10:05

PD-1 or PD-L1 Antibody + VEGF Targeted Therapy

Amishi Shah, MD

10:15

A Sequential Therapy of VEGFR-TKI Followed by Immune Checkpoint Inhibitor(s)

Pavlos Msaouel, MD, PhD

10:25

Debate on the Role of Cytoreductive Nephrectomy (CN) in the Era of Immune Checkpoint Inhibitors and Targeted Therapies

Pro: There is Still a Role for CN in the Era of Immune Checkpoint Inhibitors (ICI) and Targeted Therapies

Robert Uzzo, MD

Con: CN Should No Longer be Considered Standard of Care in the Era of ICI and Targeted Therapies

Eric Jonasch, MD

10:50

Update on Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma: Have We Made Any Progress?

Nizar M. Tannir, MD

11:05 Question and Answer Session

11:20

Case Presentations Moderator: Christopher G. Wood, MD

Panelists: Kamran Ahrar, MD; Jianjun Gao, MD, PhD; Eric Jonasch, MD;

Jose A. Karam, MD; Surena Matin, MD; Amishi Shah, MD;

Nizar M. Tannir, MD; Jeffrey J. Tomaszewski, MD and

Robert Uzzo, MD

12:05 pm Lunch (Provided)

SESSION II: Rare GU Tumors

Moderators: Curtis A. Pettaway, MD and Amishi Shah, MD

Advanced Urethral Cancer- What is the Best Local Control Strategy? Case of Advanced Urethral Tumor

1:00

Chemotherapy Role and Considerations

Amishi Shah, MD

1:10

Consolidation Residual Disease

Radiation is Best

Patricia J. Eifel, MD

Surgery is Best

Curtis A. Pettaway, MD

Case of Advanced Urethral Tumor-Continued Advanced Penile Cancer

1:30

Role of Adjuvant Radiotherapy in Penile Cancer-Who Benefits?

Karen Hoffman, MD

1:45

Update on the InPACT Trial

Curtis A. Pettaway, MD

2:00

When Chemotherapy Fails- What's Next?

Jad Chahoud, MD

2:15

Question and Answer Session

2:30

Break

Advanced Germ Cell Tumor

3:00

Postchemotherapy RPLND for Germ Cell Tumors: Indications, Outcomes

and Complications

Jose A. Karam, MD

3:15

Stem cell Transplant in Advanced GCT

Yago Nieto, MD, PhD

3:30

Case Presentations

Matthew T. Campbell, MD

3:50

Break

4:00

Andrew C. von Eschenbach Lecture Series

Robert Uzzo, MD

Distinguished Alumni Lectures

4:40

Department of Urology

David A. Swanson Distinguished Alumni Lecture Series

M. Derya Balbay, MD (Class of 1999)

Department of GU Medical Oncology

Vasiliki Tzelepi, MD (Class of 2010)

5:30 pm Adjourn/Reception

Saturday November 2, 2019

7:00 am Registration/Continental Breakfast

7:50

Welcome/Opening Remarks

Jose A. Karam, MD; Matthew T. Campbell, MD and Brian F. Chapin, MD

SESSION III: Bladder/Upper Tract Cancers

Moderators: Neema Navai, MD and Arlene O. Siefker-Radtke, MD

Upper Tract Urothelial Carcinoma

8:00

Clinical and Translational Updates in Upper Tract Urothelial Carcinoma

Surena Matin, MD

Non-Muscle-Invasive Bladder Cancer (NMIBC) and Muscle-Invasive-Bladder Cancer (MIBC)

8:15 8:30 8:45

9:05 9:20 9:35 9:45 9:55 10:05

Clinically Node Positive Bladder Cancer- When Should Surgery Be Applied?

Neema Navai, MD

Can Some Patients with MIBC be Cured with Systemic Therapy Alone?

Matthew T. Campbell, MD

Trimodal Therapy or Radical Cystectomy: Which Provides Best Local Control?

Trimodal Therapy

Chad Tang, MD

Radical Cystectomy

H. Barton Grossman, MD

Challenges and Opportunities in the BCG Shortage Era

Ashish Kamat, MD

Gene Therapy for Bladder Cancer ? From Bench to Bedside

Colin P. Dinney, MD

Case Presentations: NMIBC

Neema Navai, MD

Case Presentations: MIBC

Ashish Kamat, MD

Question and Answer Session

Break

* Indicates ethics credit

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download